Intellia Therapeutics (NTLA) Current Leases (2019 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Current Leases of $19.1 million for Q1 2026, down 50.74% year-over-year from $38.8 million in Q1 2025, and down 27.89% quarter-over-quarter from $26.5 million in Q4 2025.
Intellia Therapeutics (NTLA) Current Leases (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Current Leases for 8 consecutive years, with $19.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 50.74% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 50.74% YoY), while the FY2025 annual figure was $26.5 million, up 30.79% from the prior year.
- Current Leases declined to $19.1 million in Q1 2026 per NTLA's latest filing, from $26.5 million in the prior quarter.
- Across five years, Current Leases topped out at $38.8 million in Q1 2025 and bottomed at $9.3 million in Q1 2022.
- Historically, Current Leases has averaged $19.6 million across 5 years, with a median of $18.8 million in 2024.
- Annual changes were most pronounced in 2025 — Current Leases surged 106.59% — and 2026, when it plunged 50.74%.
- Intellia Therapeutics' Current Leases stood at $16.7 million in 2022, then gained by 11.47% to $18.6 million in 2023, then climbed by 8.86% to $20.2 million in 2024, then jumped by 30.79% to $26.5 million in 2025, then slipped by 27.89% to $19.1 million in 2026.
- Business Quant data shows NTLA's Current Leases at $19.1 million in Q1 2026, $26.5 million in Q4 2025, and $27.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 23.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.34 Mn |
| Mar 31, 2026 | 19.10 Mn |
| Dec 31, 2025 | 26.48 Mn |
| Sep 30, 2025 | 27.38 Mn |
| Jun 30, 2025 | 26.99 Mn |
| Mar 31, 2025 | 38.76 Mn |
| Dec 31, 2024 | 20.25 Mn |
| Sep 30, 2024 | 19.18 Mn |
| Jun 30, 2024 | 18.96 Mn |
| Mar 31, 2024 | 18.76 Mn |
| Dec 31, 2023 | 18.60 Mn |
| Sep 30, 2023 | 17.07 Mn |
| Jun 30, 2023 | 16.75 Mn |
| Mar 31, 2023 | 16.33 Mn |
| Dec 31, 2022 | 16.69 Mn |
| Sep 30, 2022 | 13.55 Mn |
| Jun 30, 2022 | 9.57 Mn |
| Mar 31, 2022 | 9.34 Mn |
| Dec 31, 2021 | 9.11 Mn |
| Sep 30, 2021 | 8.71 Mn |